The Manufacturers Life Insurance Company Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

The Manufacturers Life Insurance Company cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 23.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,225 shares of the company's stock after selling 9,790 shares during the period. The Manufacturers Life Insurance Company owned about 0.11% of Krystal Biotech worth $5,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Key Financial Inc purchased a new position in Krystal Biotech in the 2nd quarter worth approximately $28,000. GAMMA Investing LLC raised its position in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after buying an additional 163 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the third quarter worth $53,000. Finally, Quest Partners LLC purchased a new position in Krystal Biotech during the second quarter valued at $71,000. 86.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on KRYS. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Citigroup raised their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. William Blair raised Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Stifel Nicolaus upped their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $202.29.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.10% of the company's stock.

Krystal Biotech Trading Up 3.1 %

NASDAQ:KRYS traded up $5.49 during midday trading on Friday, hitting $185.25. 216,759 shares of the company traded hands, compared to its average volume of 322,696. The firm has a market capitalization of $5.33 billion, a P/E ratio of 101.56 and a beta of 0.80. The firm's fifty day moving average is $181.10 and its 200-day moving average is $184.26. Krystal Biotech, Inc. has a 12-month low of $101.34 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. The business's revenue for the quarter was up 879.9% on a year-over-year basis. On average, research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).